Table 1. Treatment schedule of melanoma lesions.

	day -82		day -62	day -28	day -12		day 1
	target lesion				target lesion
	p.m.	i.l.n.m.			p.m.	i.l.n.m.
treatment
rituximab in plantar lesion							2×10 mg
rituximab in popliteal lesion							3×10 mg
rituximab in inguinal lesion
dacarbazine			1g/m2	1g/m2
biopsy				plantar lesion
CT and MRI scans	n.a.	15 mm			4.7x2 cm	19 mm
	day 7	day 15	day 20	day 29	day 36	day 48	day80
							target lesion		RECIST
							p.m.	i.l.n.m.
treatment
rituximab in plantar lesion	1×10 mg	1×10 mg	1×10 mg	1×10 mg	1×40 mg	1×40 mg
rituximab in popliteal lesion	2×10 mg	2×10 mg	2×10 mg	2×10 mg	2×40 mg	2×40 mg
rituximab in inguinal lesion	1×10 mg	2×10 mg	2×10 mg	2×10 mg	2×40 mg	2×40 mg
dacarbazine			1 g/m2			1 g/m2
biopsy					plantar lesion
CT and MRI scans							1.3×1.1 cm	1.2 cm	PR
	day 101	day 129	day 187	day 194			day 228
							target lesion		RECIST
							p.m.	i.l.n.m.
treatment
rituximab i.v.	187.5mg/m2	375mg/m2
rituximab in plantar lesion
rituximab in popliteal lesion
rituximab in inguinal lesion			2×40 mg	2×40 mg
dacarbazine	1 g/m2	1 g/m2
biopsy								surgery
CT and MRI scans							CR	0.9 cm	PR

p.m., popliteal metastasis; i.l.n.m., inguinal lymph node metastasis; n.a., not applied; PR, partial remission; CR, complete remission.